Claims for Patent: 9,408,926

Summary for Patent: 9,408,926

Title:	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
Abstract:	The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K.sub.D<1 .mu.M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.
Inventor(s):	Arbogast; Christophe (Viuz-en-Sallaz, FR), Bussat; Philippe (Pers-Jussy, FR), Fan; Hong (Helen) (Shanghai, CN), Khurana; Sudha (Santa Clara, CA), Linder; Karen E. (Kingston, NJ), Marinelli; Edmund R. (Tucson, AZ), Nanjappan; Palaniappa (Princeton, NJ), Nunn; Adrian D. (Lambertville, NJ), Pillai; Radhakrishna K. (Cranbury, NJ), Pochon; Sibylle (Troinex, CH), Ramalingam; Kondareddiar (Stockbridge, GA), Shrivastava; Ajay (Princeton, NJ), Song; Bo (Princeton, NJ), Swenson; Rolf E. (Princeton, NJ), Von Wronski; Mathew A. (Geneva, CH), Yan; Feng (Grand-Lancy, CH)
Assignee:	Bracco Suisse S.A. (Manno, CH)
Application Number:	14/085,645
Patent Claims:	1. A method for adjusting a treatment protocol comprising: (a) administering an ultrasound contrast agent comprising a KDR binding polypeptide having a sequence selected from the group consisting of: TABLE-US-00047 AGPKWCEEDWYYCMITGTGGGK; (SEQ ID NO: 264) GDSRVCWEDSWGGEVCFRYDPGGGK; (SEQ ID NO: 294) AQDWYYDEILSMADQLRHAFLSGGGK; (SEQ ID NO: 310) AGPTWCEDDWYYCWLFGTGGGK; (SEQ ID NO: 277) AGDWWVECRVGTGLCYRYDTGTGGGK; (SEQ ID NO: 286) AGPTWCADDWYYCWLFGTGGGK; (SEQ ID NO: 390) and VCWEDSWGGEVCFRYDPGGGK. (SEQ ID NO: 337) to a subject with a disorder associated with cell hyperproliferation or angiogenesis; (b) obtaining an initial image of the subject; (c) administering a therapeutic agent appropriate for the treatment of the disorder; (d) obtaining a subsequent image of the subject; (e) comparing the initial and the subsequent images to evaluate the effectiveness of the therapy; (f) determining whether the effectiveness of the therapy is adequate; and (g) if the effectiveness of the therapy is determined not to be adequate, adjusting said treatment protocol, terminating said treatment protocol or administering a different treatment protocol. 2. The method of claim 1, wherein the disorder is cancer. 3. The method of claim 1, wherein the ultrasound contrast agent comprises one or more KDR binding dimers selected from the group consisting of: Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:337) (JJ-C(.dbd.O)(CH.sub.2).sub.3C(.dbd.O)--K--NH(CH.sub.2).sub.4--(S)--CH((A- c-AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO:277))-NH)CONH.sub.2)--NH.sub.2), a dimer comprising Ac-GDSRVCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:294) and Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO:277), and Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO:277){Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:337) [JJ-Glut-K(SATA)]-NH.sub.2}--NH.sub.2. 4. The method of claim 1, wherein the ultrasound contrast agent comprises a dimer. 5. The method of claim 3, wherein the dimer is Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:337) (JJ-C(.dbd.O)(CH.sub.2).sub.3C(.dbd.O)--K--NH(CH.sub.2).sub.4--(S)-CH((Ac- -AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO:277))-NH)CONH.sub.2)--NH.sub.2). 6. The method of claim 1, wherein the initial and subsequent images are obtained via diagnostic ultrasound. 7. The method of claim 1, wherein the therapeutic agent is an anti-cancer agent. 8. The method of claim 7, wherein the cancer is selected from the group consisting of prostate cancer, mammary cancer, ovarian cancer, liver cancer, colon cancer, renal cancer, bone cancer, bladder cancer, pancreatic cancer, lung cancer, uterine cancer and testicular cancer. 9. The method of claim 2, wherein comparing the initial and subsequent images to evaluate the effectiveness of therapy comprises comparing the size or vascularity of a tumor shown in the images of the subject. 10. The method of claim 2, wherein comparing the initial and subsequent images to evaluate the effectiveness of therapy comprises comparing a parameter selected from the group consisting of Imax (maximal peak enhancement values), AUC (area under the curve), WIR (Wash-in-rate), and TTP (Time-to Peak). 11. The method of claim 2, wherein comparing the initial and subsequent images to evaluate the effectiveness of therapy comprises comparing LPO (late phase opacification). 12. The method of claim 7, wherein the anti-cancer agent is selected from the group consisting of sunitinib, imatinib, sorafenib and bevacizumab. 13. The method of claim 1, wherein the ultrasound contrast agent comprises a microvesicle filled with a gas or gas mixture. 14. The method of claim 13, wherein the ultrasound contrast agent comprises a microbubble filled with a gas or gas mixture. 15. The method of claim 13, wherein the gas or gas mixture comprises fluorinated gas. 16. The method of claim 14 wherein the gas or gas mixture comprises at least one gas selected from the group consisting of air, nitrogen, oxygen, carbon dioxide, argon, xenon, krypton, a hyperpolarized gas, SF.sub.6, a freon and a perfluorocarbon. 17. The method of claim 15 wherein the gas comprises SF.sub.6 or C.sub.4F.sub.10. 18. The method of claim 14 wherein the gas-filed microbubble comprises at least one phospholipid. 19. The method of claim 18 wherein the phospholipid is selected from DPPE, DSPE and DMPE. 20. The method of claim 18 wherein the phospholipid is a saturated phospholipid. 21. The method of claim 14, wherein the gas or gas mixture comprises fluorinated gas. 22. The method of claim 5, wherein comparing the initial and subsequent images to evaluate the effectiveness of therapy comprises comparing a parameter selected from the group consisting of Imax (maximal peak enhancement values), AUC (area under the curve), WIR (Wash-in-rate), and TTP (Time-to Peak). 23. The method of claim 5, wherein comparing the initial and subsequent images to evaluate the effectiveness of therapy comprises comparing LPO (late phase opacification).

Details for Patent 9,408,926

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2022-03-01